Generic drug maker, Mylan Inc, will pay the U.S government $121 million to settle a civil dispute, started by a whistleblower, involving Medicaid rebates on drug sales from 2000 to 2004.

The dispute called into question whether an authorized generic medicine is subject to the generic rate that Mylan paid on sales from 2000 to 2004, or a higher innovator rate. Mylan was treating its authorized generics as traditional generics, a practice they began before government guidelines were put in place.

The whistleblower, Ven-A-Care, a pharmacy in Key West, Florida, will receive $10.8 million as its share of the recovery.